Secukinumab efficacy in the treatment of nail psoriasis: a case series

Pistone, Giuseppe; Gurreri, Rosario; Tilotta, Giovanna; Castelli, E.; Bongiorno, Maria Rita

doi:10.1080/09546634.2018.1529381

Search citation statements

Order By: Relevance

Paper Sections

Select...

Secukinumab1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2023

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase 2, double-blind, placebo-controlled, clinical trial evaluating the efficacy of secukinumab (fully human monoclonal antibody) for patients with moderate to severe plaque PsO of the hands, feet, and nails revealed improvement in patients' disease thus far [46]. Improvement of NAPSI has been reported to be even more rapid in a case series of 15 patients, with a 50% reduction at 6 weeks and an 80% reduction at 12 weeks [47]. A recent case report suggests that secukinumab might also have good efficacy in children with nail PsO [48].…”

Section: Secukinumabmentioning

confidence: 99%

Small Molecules and Biologics in the Treatment of Nail Psoriasis

Rigopoulos

Stathopoulou

Gregoriou³

2020

Skin Appendage Disord

View full text Add to dashboard Cite

Nail psoriasis (PsO) is a disorder with profound impact on patients’ quality of life. Several challenges and unmet needs remain in the treatment of nail PsO. Introduction of biologics and small molecules in the treatment of nail PsO has allowed for rapid control of the disease and high efficacy. The aim of this review was to present the published studies on nail PsO therapy with biologics and small molecules and illuminate the results in the studies where the design and outcome evaluation had nail PsO in the forefront.

show abstract

Section: Secukinumabmentioning

confidence: 99%